A bill to reauthorize and expand the Food and Drug Administration's user-fee programs easily passed the House of Representatives 387-5 Wednesday evening.
The program allows the agency to collect fees from the healthcare sectors it regulates in exchange for agreeing to meet certain performance goals related to timely consideration of their product marketing applications. Federal law requires reauthorization of the user-fee programs every five years.
Read the full story: http://hcp.lv/KLEuHj
Source: ModernHealthcare.com
The measure was amended from a version that the Energy and Commerce Committee approved earlier in May to accelerate the availability of generics. The change to the bill would reduce the federal deficit by $340 million over 10 years, instead of adding $247 million to the deficit, according to the Congressional Budget Office.
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More